Business Context and Reporting Period
This summary covers Becton, Dickinson and Company's (BD) Form 10-Q for the quarterly period ended March 31, 2026. The reporting period is significantly impacted by the completion of a major corporate restructuring on February 9, 2026: the spin-off of BD's former Biosciences and Diagnostic Solutions business (Life Sciences segment) and its combination with Waters Corporation in a Reverse Morris Trust transaction. Consequently, the historical results of the Life Sciences segment are presented as discontinued operations. Post-separation, BD operates four remaining segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2026 | Six Months Ended Mar 31, 2026 |
|---|---|---|
| Revenues (Continuing Ops) | $4,714 million | $9,200 million |
| Operating Income (Continuing Ops) | $93 million | $562 million |
| Net (Loss) Income (Continuing Ops) | $(37) million | $274 million |
| Net (Loss) Income (Total) | $(311) million | $72 million |
| Diluted EPS (Continuing Ops) | $(0.13) | $0.96 |
| Diluted EPS (Total) | $(1.11) | $0.25 |
| Cash from Operating Activities | N/A | $1,328 million |
| Total Debt | $17,279 million | $17,279 million |
| Cash & Equivalents (incl. restricted) | $1,015 million | $1,015 million |
Note: Total Net Loss for the quarter was driven by a $(274) million loss from discontinued operations.
Material Changes vs. Prior Period
- Revenue Growth: Revenues from continuing operations increased 5.2% year-over-year for the quarter and 4.4% for the six-month period. Growth was driven by volume/mix and favorable foreign currency impacts, partially offset by market dynamics in China (volume-based procurement) and lower vaccine demand.
- Profitability Decline: Operating income from continuing operations dropped significantly from $383 million in Q2 2025 to $93 million in Q2 2026. This was primarily due to a $533 million charge for integration, restructuring, and transaction expenses, compared to $93 million in the prior year.
- Restructuring Charges: The company recorded $450 million in non-cash asset impairment charges related to exiting operational activities not aligned with its "Excellence Unleashed" strategy.
- Discontinued Operations: The spin-off resulted in a $(274) million loss from discontinued operations for the quarter, compared to $150 million income in the prior year, reflecting the separation costs and the removal of the Life Sciences segment's earnings.
- Debt Reduction: Total debt decreased to $17.3 billion from $19.2 billion at the end of fiscal 2025. BD used $2 billion of the $4 billion cash distribution from the spin-off to repay debt.
Guidance, Outlook, and Risks
Management Commentary & Strategy: BD is executing its "Excellence Unleashed" strategy, focusing on competing, innovating, and delivering operational excellence. Management expects continued adverse impacts from tariffs on operating expenses for fiscal 2026. The company remains committed to returning value to shareholders, having repurchased $2.25 billion of stock and paid $589 million in dividends in the first six months of 2026.
Key Risks and Contingencies:
- Regulatory Actions: BD received an FDA Warning Letter in April 2026 regarding its El Paso facility (ChloraPrep and PurPrep products), citing deficiencies in manufacturing practices. BD has voluntarily placed these products on ship hold in the U.S. pending testing. A prior Warning Letter regarding the San Diego facility (Pyxis products) remains open with an accrued liability of $68 million.
- Litigation: The company faces significant product liability claims, including approximately 6,995 hernia repair device claims and 3,250 implantable port claims. Total accruals for product liability and legal matters were approximately $1.7 billion as of March 31, 2026.
- Macroeconomic Factors: Risks include tariffs, supply chain disruptions, geopolitical instability (Middle East), and cost-containment measures in healthcare markets, particularly in China.
Investor Verification Checklist
- Spin-Off Accounting: Verify the classification of the Life Sciences segment as discontinued operations and the impact of the $4 billion cash distribution on the balance sheet and equity.
- Restructuring Impact: Assess the $450 million non-cash impairment charge and its effect on future depreciation/amortization and segment profitability.
- FDA Warning Letters: Monitor the resolution of the El Paso and San Diego facility Warning Letters, specifically the potential for product recalls, consent decrees, or further regulatory action.
- Legal Accruals: Review the $1.7 billion litigation accrual and the potential for charges in excess of current estimates, particularly regarding hernia and port liability claims.
- Tariff Exposure: Evaluate the company's ability to mitigate tariff costs through sourcing optimization and exemptions, as management expects continued adverse impacts in 2026.